comparemela.com

Latest Breaking News On - இதய வடிகுழாய் - Page 5 : comparemela.com

Merit Health unveils new Cardiac Catheterization Lab

Merit Health unveils new Cardiac Catheterization Lab Merit Health unveils new Cardiac Catheterization Lab By Melissa Rademaker | February 12, 2021 at 5:45 PM CST - Updated February 12 at 7:16 PM HATTIESBURG, Miss. (WDAM) - Just in time for American Heart Health month, Merit Health Wesley has opened a newly rebuilt Cardiac Catheterization Lab. A cardiac cath exam provides information on how well a patient’s heart works. It can identify problems and allow for procedures to open blocked arteries and combat other forms of heart disease. The $1.6 million dollar lab offers state-of-the-art technology. “It’s a high-quality imaging lab certainly,” cardiologist Allen Covin said. “One of the main benefits is there’s a lot lower radiation to the patient and to the staff, that’s probably the main benefit with the imaging and the quality.”

Celebrating three years of care for the local community

St Vincent’s Private Hospital Werribee is excited to have been working with the local community for three years. Since opening in 2018, the purpose built facility has provided high-quality healthcare to almost 13,000 patients and performed more than 8000 surgical procedures. The hospital has been designed and built to meet the pressing healthcare needs of Melbourne’s outer-western suburbs, becoming one of the region’s most modern acute care private hospitals. St Vincent’s Private Hospital Werribee is conveniently located in the Hoppers Lane health precinct opposite the Werribee Mercy Hospital. The hospital offers an extensive range of health services to help support the local community to access care closer to home.

Global Transcatheter Heart Valve Replacement and Repair Market 2020 Industry Analysis - Edwards Lifesciences, Boston Scientific, Medtronic, Braile Biomedica

Global Transcatheter Heart Valve Replacement and Repair Market 2020 Industry Analysis - Edwards Lifesciences, Boston Scientific, Medtronic, Braile Biomedica
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.

Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases

(1) - Clinical utility of Axumin (fluciclovine F 18) being investigated in expanded areas of cancer imaging - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced that the first patient has been dosed in its Phase 3 REVELATE clinical trial of 18F-fluciclovine, a positron emission tomography (PET) imaging radiopharmaceutical being studied for potential use in detecting recurrent brain metastases. The REVELATE study is a Phase 3, multi-center, single-arm imaging study being conducted in the United States. Its purpose is to assess the diagnostic performance of 18F-fluciclovine PET in detecting recurrent brain metastases in patients previously treated with radiation therapy. The first patient dosed in the study was at Yale University, New Haven, Conn., under the auspices of Dr. Mariam Aboian, Assistant Professor of Radiology.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.